Facts and Figures 2008Medicines and Health Care
The Norwegian Association of Pharmaceutical Manufacturers (LMI)
Facts and Figures 2008 – Medicines and Health Care
1.01 The number of marketing authorisations, active ingredients and medicines in Norway
0
1 000
2 000
3 000
4 000
5 000
6 000
7 000
8 000
9 000
Number omMANumber of medicinesNumber of active ingredients
200720062005200420032002
Source: The Norwegian Medicines Agency
Year
Num
ber
1 316 1 354 1 371 1 387 1 414 1 4491 396 1 507 1 6451 838 1 994
2 145
8 004
6 829
6 3926 046
5 303
4 562
Facts and Figures 2008 – Medicines and Health Care
1.02 New and withdrawn active ingredients
Year New active substancesWithdrawn active
ingredients
2000 36 *
2001 45 *
2002 48 *
2003 24 *
2004 29 12
2005 25 13
2006 47 20
2007 51 16
Source: The Norwegian Medicines Agency
*Number not available
Facts and Figures 2008 – Medicines and Health Care
1.03 Pharmaceutical sales in Norway in the last few years, 2007-currency
10 000
11 000
12 000
13 000
14 000
15 000
16 000
17 000
18 000
19 000
20 000
20072006200520042003200220012000
Year
Mill
.NO
K
16 90016 55016 60016 450
15 35015 300
13 850
12 850
Source: LMI/Farmastat and Statistics Norway Figures in 2007-currency
Facts and Figures 2008 – Medicines and Health Care
1.04 Sales growth by value
-2%
0%
2%
4%
6%
8%
10%
12%
14%
Groth in fixed pricesNominal growth
20072006200520042003200220012000
Year
Per
cent
age
grow
th
Source: Statistics Norway - LMI/Farmastat
6,5%
11,4%11,8%
2,8%
7,5%
2,5%1,9%
3,0%
2,3%
-0,4%
0,9%
7,1%
0,4%
10,4%
8,1%
3,3%
Facts and Figures 2008 – Medicines and Health Care
1.05 Sales growth by volume (DDD)
0%
1%
2%
3%
4%
5%
6%
7%
8%
9%
200720062005200420032002200120001999
Sal
esgr
owth
DD
D
Source: LMI/Farmastat
Year
Growth measured by DDD
8,0%
6,2%
7,3%7,7%
3,4%
5,9%
4,5%4,1%
4,7%
Facts and Figures 2008 – Medicines and Health Care
1.06 The Norwegian pharmaceutical market by main therapeutic groups (ATC)
Sales PPP 2007,NOK Million
Growth2006-2007
Share of totalsales 2007
N Central nervous system 2 163,7 4,7 % 19,9 %
LAntineoplastic and immuno-modulatingagents
1 998,3 12,4 % 18,4 %
C Cardiovascular system 1 431,5 -4,9 % 13,2 %
A Alimentary and metabolism 1 141,6 -1,3 % 10,5 %
R Respiratory system 1 105,9 0,6 % 10,2 %
B Blood and bloodforming organs 671,6 6,4 % 6,2 %
G Urogenitals and sex hormones 579,2 4,4 % 5,3 %
J Systemic antiinfectives 557,2 3,1 % 5,1 %
M Musculo-skeletal system 327,8 -11,9 % 3,0 %
H Systemic hormones excl. sex hormones 274,9 3,1 % 2,5 %
S Sensory organs 235,1 0,5 % 2,2 %
D Dermatologicals 232,3 8,9 % 2,1 %
V Various 114,4 0,0 % 1,1 %
P Antiparasitic products 32,7 11,0 % 0,3 %
Total 10 866,1 2,9 % 100,0 %
Source: LMI/Farmastat
Facts and Figures 2008 – Medicines and Health Care
1.07 The top 25 Pharmaceutical companies on the Norwegian market
Rank 2007(2006) Company
Total sales 2007PPP, NOK mill. Sales growth Market share
1 (1) Pfizer AS 932,6 -13,9 % 8,6 %
2 (2) AstraZeneca AS 873,0 10,2 % 8,0 %
3 (3) GlaxoSmithKline AS 731,9 -3,8 % 6,7 %
4 (10) Schering-Plough AS 584,5 46,5 % 5,4 %
5 (5) Novartis Norge AS 566,4 12,9 % 5,2 %
6 (6) Wyeth Norge 446,4 -6,0 % 4,1 %
7 (8) MSD (Norge) AS 435,1 1,7 % 4,0 %
8 (4) sanofi-aventis 430,5 -17,1 % 4,0 %
9 (9) Nycomed Pharma AS 417,6 0,0 % 3,8 %
10 (11) Roche Norge A/S 347,1 3,2 % 3,2 %
11 (7) *Farmagon AS 315,2 -32,4 % 2,9 %
12 (12) Eli Lilly Norge AS 314,8 9,5 % 2,9 %
13 (13) Novo Nordisk Scandinavia AS 264,3 2,4 % 2,4 %
14 (16) Abbott Norge as 254,8 7,8 % 2,3 %
15 (17) Weifa AS 252,6 7,9 % 2,3 %
16 (-) Bayer Schering Pharma 249,8 - 2,3 %
17 (15) J anssen-Cilag AS 240,0 -0,8 % 2,2 %
18 (14) Alpharma AS 228,2 -6,6 % 2,1 %
19 (-) Bristol-Myers Squibb Norway Ltd 174,8 - 1,6 %
20 (20) Boehringer Ingelheim Norway KS 168,0 11,2 % 1,5 %
21 (22) H. Lundbeck A/S 154,9 13,8 % 1,4 %
22 (-) Merck Serono 144,1 - 1,3 %
23 (19) ratiopharm AS 134,3 -15,8 % 1,2 %
24 (-) Amgen 129,1 - 1,2 %
25 (-) LEO Pharma AS 111,4 - 1,0 %
Aggregate sales top 25 companies 8 901,4 - 81,9 %
Aggregate sales all companies 10 866,1 2,9 % 100,0 %
Source: LMI/Farmastat* Parallell importers
Facts and Figures 2008 – Medicines and Health Care
1.08 The top 25 medicines on the Norwegian market in terms of sales value
Rank 2006(2005) Medicine
Sales 2006PPP, NOKmill.
Salesgrowth
Share oftotal sales Area of application
1 (1) Enbrel 340,9 3,46 % 3,1 % Rheumatoid arthritis
2 (5) Remicade 245,8 24,99 % 2,3 % Rheumatoid arthritis
3 (4) Seretide 242,3 -4,31 % 2,2 % Asthma
4 (2) Lipitor 167,2 -29,07 % 1,5 % High cholesterol
5 (8) Humira 159,3 26,47 % 1,5% Rheumatoid arthritis
6 (6) SymbicortTurbuhaler 137,0 10,43% 1,3 % Asthma
7 (7) Zyprexa 130,1 6,93 % 1,2 % Schizophrenia
8 (11) Cipralex 115,8 17,97 % 1,1 % Depression
9 (9) Selo-Zok 101,2 -5,91 % 0,9 % High blood pressure
10 (14) Paracet 97,5 15,62 % 0,9 % Pain
11 Nexium 87,3 63,43% 0,8 % Gastric ulcer
12 (18) Atacand 82,9 83,59 % 0,8 % High blood pressure
13 (17) Cozaar 80,3 5,14 % 0,7 % High blood pressure
14 (15) Lamictal 80,3 -4,58 % 0,7 % Epilepsy
15 (22) Otrivin 79,8 11,67 % 0,7 % Nasal congestion
16 (-) Mabthera 78,1 17,81 % 0,7 % Cancer andRheumatoid arthritis
17 (19) Cozaar Comp 77,1 2,04 % 0,7 % High blood pressure
18 (16) Insulatard 76,0 -3,56 % 0,7 % Diabetes
19 (24) Herceptin 75,5 13,08 % 0,7 % Cancer
20 (20) Plavix 74,3 -0,06 % 0,7 % Thrombosis
21 (-) Ibux 73,6 16,86 % 0,7 % Pain
22 (22) Rebif 73,5 4,08 % 0,7 % Multiple sclerosis
23 (25) Singulair 71,7 7,63 % 0,7 % Asthma
24 NexiumFarmagon 70,3 -62,52 % 0,6 % Gastric ulcer
25 (-) Coaprovel 66,0 24,52 % 0,6 % High blood pressure
Aggregate sales top 25 medicines 2 883,8 26,6 %
Aggregate sales all medicines 10 866,1 2,9 % 100,0 %
Source: LMI/FarmastatParalell import is not included. The growth rate for some products willreflect variations in the splitbetween direct and paralell imports.
Facts and Figures 2008 – Medicines and Health Care
1.09 The top 25 active ingredients as measured by defined daily doses (DDD)
Rank2006(2005) Active ingredient
Name oforiginalmedicine
SalesDDD/1000inhab./
Growth06-07DDD Area of application
1 (1) Simvastatin Zocor 110,2 28,6 % High cholesterol
2 (3) Acetylsalicylic acid Albyl-E 67,9 5,5 % Thrombosis
3 (2) Natriumfluorid - 67,6 -5,1 % Caries
4 (4) Atorvastatin Lipitor 49,5 -3,5 % High cholesterol
5 (5) Levonorgestrel - 37,3 8,3 % Contraception
6 (6) Ascorbic acid - 33,7 3,4 % Vitamin deficiency
7 (7) Zopiklon Imovane 32,8 5,2 % Insomnia
8 (8) Amlodipin Norvasc 32,0 5,7 % High blood pressure
9 (10) Cetirizin - 30,2 17,1 % Allergy
10 (9) Paracetamol - 28,4 12,0 % Pain
11* Xylometazolin Otrivin 27,8 - Nasal congestion
12 (12) Ramipril Triatec 25,2 6,0 % High blood pressure
13 (11) Metoprolol Selo-Zok 25,1 4,7 % High blood pressure
14 (13) Vitamin B complex - 23,3 3,7 % Vitamin deficiency
15 (15) Thyroxin - 22,4 4,9 % Hypothyreosis
16 (14) Furosemid Lasix Retard 20,7 -4,9 % High blood pressure
17 (20) Escitalopram Cipralex 16,5 27,6 % Depression
18 (18) Ibuprofen - 16,4 18,7 % Pain
19 (21) Kandesartan Atacand 15,2 17,1 % High blood pressure
20 (24) Drospirenon and oestrogen Yasmin 14,5 15,2 % Contraception
21 (17) Esomeprazol Nexium 13,9 -14,8 % Gastric ulcer
22 (16) Levonorgestrel and oestrogenTrinetta 12,9 - Contraception
23 (22) Codein, combinations - 12,8 -0,5% Pain
24 (25) Losartan and diuretic Cozaar Comp 12,7 3,2 % High blood pressure
25 (23) Enalapril Renitac 12,6 -1,7 % High blood pressure
Sum 761,5 -
Total sales 1 595,0 4,7 %
Share of total market 47,8 % -
Figures from2007 Source: LMI/Farmastat
*Market leader given for some active ingredients
Facts and Figures 2008 – Medicines and Health Care
1.10 The split of sales within the distribution chain
V.A.T.20,0%
Pharmacy15,3%
Wholesaler8,5%
Manufacturer56,2%
Source: LMI/Farmastat Covers sales through pharmaciesEstimate for 2007
Facts and Figures 2008 – Medicines and Health Care
1.11 Market share og generics (DDD)
0%
5%
10%
15%
20%
25%
30%
35%
40%
20072006200520042003200220012000
37,2%35,4%
31,8%
27,8%
24,0% 23,6% 23,3%25,1%
Sha
reof
tota
lsal
es
Year
Source: LMI/Farmastat
Facts and Figures 2008 – Medicines and Health Care
1.12 Generics` share of the generics interchangeable market
0%
10%
20%
30%
40%
50%
60%
70%
80%
Value PPPDDD
2007200620052004
Sha
re
Year
Source: LMI/FarmastatExcluding Parallell imported medicines
Figures in PPP/DDD
31,0%
47,6%
30,5%
54,2%
46,2%
70,8%
46,4%
72,3%
Facts and Figures 2008 – Medicines and Health Care
1.13 Market share for parallel imported medicines
Per
cent
Source: LMI/Farmastat
0%
1%
2%
3%
4%
5%
6%
7%
8%
2007200620052004200320022001200019991998199719961995
År
0,2%
4,3%
5,9%
6,9%
6,2%
6,6%6,3%
5,1%
7,7%
6,6%
7,0%
1,4%
3,4%
Facts and Figures 2008 – Medicines and Health Care
1.14 Market share for Wholesalers
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
50%
Apokjeden distribusjon AS - Tamro OY/Phoenix group
Holtung AS - Alliance UnichemPLC
NMD Grossisthandel AS - Celesio AG
200720062005200420032002Year
Source: LMI/Farmastat
48,5%
15,0%
36,6%
45,3%
18,9%
35,7%
44,5%
35,2%
20,2%
45,3%
20,0%
34,8%
45,6%
20,1%
34,3%
46,4%
20,0%
33,5%
Facts and Figures 2008 – Medicines and Health Care
1.15 Pharmacy chain market share
Hospital pharmacies20,1%
Other pharmacies3,6%
Vitusapotek/Ditt Apotek24,3% Apotek 1
33,8%
Alliance apotekene18,1%
Figures from2007 Source: LMI/Farmastat
Facts and Figures 2008 – Medicines and Health Care
1.16 Pharmacy chain market share, excl. hospital pharmacies
Other pharmacies4,5%Vitusapotek/Ditt Apotek
30,4%
Apotek 142,4%
Alliance apotekene22,7%
Figures from2007 Source: LMI/Farmastat
Facts and Figures 2008 – Medicines and Health Care
1.17 Number of inhabitants per pharmacy in Europe
0 2 000 4 000 6 000 8 000 10 000 12 000 14 000 16 000 18 000 20 000
DenmarkSweden
NetherlandsNorwaySloveniaAustriaFinland
HungaryUnited Kingdom
SwitzerlandSlovakia
Czech RepublicPortugal
GermanyItaly
PolandIrelandFrance
LithuaniaSpain
BelgiumGreece 1 100
2016
2117
2302
2669
3050
3050
3330
3 800
3 800
3 930
4 036
4 435
4800
4886
6 727
6 888
7 292
8 115
9400
9 543
17 386
Figures from2006 Source: AESGP
Inhabitants per pharmacy
Facts and Figures 2008 – Medicines and Health Care
1.18 Pharmaceutical consumption (DDD) in the Nordic countries
1 000
1 200
1 400
1 600
1 800
2 000
Nordic averageNorwaySwedenFinlandDenmark
20072006200520042003
DD
Dpe
r10
00
inha
bita
nts
perda
y
Source: IMS Health
1 444
1 504 1 559
1 606
1 674
1 436
1 490
1 586
1 565
1 637
1 141
1 200
1 278
1 368
1 446
1 7191 765
1 813
1 871
1 932
1 2711 320
1 3601 410
1 474
Year
Facts and Figures 2008 – Medicines and Health Care
1.19 Leading pharmaceutical brands on the global market
Medicine nameRank 2006 (2005) Area of application
Sales US$Billion Growth %
1 (1) Lipitor High cholesterol 13,6 4,2 %
2 (3) Nexium Gastric ulcer and reflux 6,7 16,9 %
7 (9) Seretide (Advair) Asthma and COPD 6,3 10,3 %
4 (2) Plavix Prevention of cardovascular events 5,8 -3,4 %
5 (6) Norvasc High blood pressure 5,0 -0,5 %
6 (-) Aranesp Anemia 5,0 35,6 %
7 (7) Zyprexa Schizophrenia 4,7 -0,4 %
8 (-) Risperdal Psychosis and behavioural disorders 4,6 12,3 %
9 (-) Enbrel Rheumatic diseases and skin diseases 4,5 18,4 %
10 (10) Efexor Depression 4,0 2,7 %
Aggregate top 10 medicines 60,0 8,0 %
Aggregate all medicines 643,0 7,0 %
Source: IMS Health Data from 2006Figures in ex-factory prices
Facts and Figures 2008 – Medicines and Health Care
1.20 The Norwegian medicines market in relation to Europe
Country, Rank 2005 Sales million Euro, 2005 Share
1 Germany 24 846 19,2 %
2 France 23 838 18,4 %
3 Italy 15 749 12,2 %
4 UK 15 569 12,0 %
5 Spain 11 332 8,7 %
6 Greece 3 821 3,0 %
7 The Netherlands 3 795 2,9 %
8 Belgium 3 657 2,8 %
9 Portugal 3 105 2,4 %
10 Switzerland 2 709 2,1 %
11 Sweden 2 673 2,1 %
12 Austria 2 411 1,9 %
13 Finland 1 740 1,3 %
14 Denmark 1 536 1,2 %
15 Ireland 1 514 1,2 %
16 Norway 1 304 1,0 %
Aggregate 129 515 100,0 %
Source: EFPIA Figures in ex-factory prices or PPP
Facts and Figures 2008 – Medicines and Health Care
1.21 Leading pharmaceutical companies on the global market
Facts and Figures 2008 – Medicines and Health Care
2.01 Changes in prices of medicines and general inflation
-6%
-5%
-4%
-3%
-2%
-1%
0%
1%
2%
3%
4%
Medicines
Consumer Price Index
20072006200520042003200220012000
Sources: Statistics Norway and LMI/Farmastat
Pric
ech
ange
%
Year
0,8%
2,3%
1,6%
0,4%
2,5%
1,3%
3,0%3,1%
-1,6%
-4,0%
-2,3%
0,2%
-5,3%
-0,7%
-2,0%-2,3%
Facts and Figures 2008 – Medicines and Health Care
2.02 Public spending on reimbursable prescription medicines
NO
KM
illio
n
Source: NAV, Ministry of Health andCare Services, LMI
Figures for 2007 and 2008 are estimates
Year
Figures in mill. NOK, 2007-currency
0
2 000
4 000
6 000
8 000
10 000
12 000
200820072006200520042003200220012000199919981997
8 4208 211
8 591
9 2519 658
8 7688 541
7 607
7 0546 573
6 207
5 644
Facts and Figures 2008 – Medicines and Health Care
2.03 Payment for pharmaceutical consumption
Non prescription medicines11,6%Patient co-payment
6,4%
Prescription medicines(non-reimbursable)12,1%
Hospitals16,5%
Other public financing of prescription medicines1,6%
National Insurance Administration(reimburable medicines)51,8%
Sources: NAV, Norwegian Pharmacy Association,Statistics Norway, LMI/Farmastat
Figures from2006The figure is based on data from multiplesources, which resaults in some uncertainty.
Facts and Figures 2008 – Medicines and Health Care
2.04 Public health expenditure per inhabitant
0
5 000
10 000
15 000
20 000
25 000
30 000
35 000
Other Health Care expenditure Medicines Hospital services
2006200520042003200220012000
14 377
19 383 19 061 18 747 19 126 19 319 20 201
1 949
2 046 2 302 2 375 2 566 2 5802 590
7 351
3 4975 681 7 283
7 6908 449
8 611
Year
NO
Kper
inha
bita
nt
Sources: Statistics Norway, NAV 2006-currency
31 402
23 67724 925
27 04428 404
29 38230 348
Facts and Figures 2008 – Medicines and Health Care
2.05 Public spending on health care and medicines
YearGDP
NOK mill
Public spendingon health care
Public spendingon medicines % of public
spending onhealt careNOK mill % of GDP NOK mill % av GDP
2000 1 653 197 106 024 6,4 % 8 726 0,5 % 8,2 %
2001 1 664 806 111 614 6,7 % 9 161 0,6 % 8,2 %
2002 1 638 739 121 101 7,4 % 10 309 0,6 % 8,5 %
2003 1 663 729 127 195 7,6 % 10 634 0,6 % 8,4 %
2004 1 811 461 131 573 7,3 % 11 492 0,6 % 8,7 %
2005 1 983 819 135 899 6,9 % 11 554 0,6 % 8,5 %
2006 2 156 000 140 618 6,5 % 11 597 0,5 % 8,2 %
Figures in 2006 currencySources: Statistics Norway, NAV and LMI/Farmastat
Facts and Figures 2008 – Medicines and Health Care
2.06 Expenditure on medicines in the private and public sector
0
2 000
4 000
6 000
8 000
10 000
12 000
14 000
16 000
18 000
Private shareNational InsuranceHospitals
2006200520042003200220012000199919981997
Year
NO
Km
illio
n
Fixed prices, 2006-currencySources: Statistics Norway, NationalInsurance Administration and LMI/Farmastat
1584 1633 1381 1451 1430 1 574 1688 1911 20492 736
5752 6 290 65167275 7 731
8 734 89469581 9505
8861
33393656
44203999
4597
48804602
4826 4917 4803
Facts and Figures 2008 – Medicines and Health Care
2.07 Daily costs for the 25 most commonly used medicines
Facts and Figures 2008 – Medicines and Health Care
2.08 The consumer`s medicine expenses compared to other expenses
0 5 000 10 000 15 000 20 000
Pets
Flowers and gardening
Medicines
Non-alcoholic beverages
Newspapers and Magazines
Tobacco
Alcoholic beverages
Holiday trips
Tele services
Personal care
Restaurant
Clothes
Purchase of car
Food 15 826
13 827
7 157
4 752
3 345
3 206
3 049
2 795
1 555
1 376
1 308
1 281
1 114
717
Source: StatisticsNorway Average annual figures 2004-2006
NOK per inhabitant
Facts and Figures 2008 – Medicines and Health Care
2.09 National Insurance expenditure
Unemployment benefitsProfessional rehabilitationRetirement pensionDisability benefitsBasic and supplementary benefits, various aidsSickness and birth benefitsHealth care excl. medicinesSocial benefitsMedicinesMedical rehabilitationAdministrationOther Payments
Source: NAV
5,0%
37,9%
20,2%
3,2%
15,6%
4,2%
2,7%
1,3%0,1%
2,7%
3,7%
Facts and Figures 2008 – Medicines and Health Care
2.10 Health care expenditure
2001 2002 2003 2004 2005 2006
Total health care expenditure,nominal values
135 266 150 029 159 572 168 237 176 031 186 396
Total public health careexpenditure, nominal values
112 000 124 351 132 711 139 666 146 106 154 709
Publicly financed share of totalhealth care expenditure
83 % 83 % 83 % 83 % 83 % 83 %
Total private expenditure,nominal values
23 266 25 678 26 861 28 571 29 925 31 687
Publicly financed share of totalhealth care expenditure
17 % 17 % 17 % 17 % 17 % 17 %
Total expenditure medicines,nominal values
12 700 14 200 14 600 15 700 16 100 16 400
Medicines as share of totalhealth care expenditure
9,4 % 9,5 % 9,1 % 9,3 % 9,1 % 8,8 %
Total health care expenditure,fixed 2006-currency
146 466 160 385 166 504 174 770 180 007 186 396
Annual growth in health careexpenditure, fixed 2006-currency
5,3 % 9,5 % 3,8 % 5,0 % 3,0 % 3,5 %
Public health care expenditure asshare of total public expenditure
16,4 % 16,8 % 16,8 % 17,0 % 17,3 % 17,1 %
NOK mill. or percent
Sources: Statistics Norway/LMI/Farmastat
Facts and Figures 2008 – Medicines and Health Care
2.11 Intenational price index for medicines
90
95
100
105
110
115
120
125
Irelan
d
Switz
erlan
d
Denmar
k
German
y
Nethe
rland
s
UK
Swed
en
Portu
gal
AustriaItaly
Finla
nd
Norway
Fran
ce
Belgi
um
Greec
e
Spain
Inde
x,N
orw
ay=1
00
Source: LMI Data as of autumn 2005
119,8
116,8116,5
115,8
109,4108,5
107,0
104,4
103,1102,5
101,0100,0
99,0
97,897,5
92,0
Facts and Figures 2008 – Medicines and Health Care
2.12 VAT on medicines and other goods and services in Europe
CountryStandardVAT %
VAT on medicines %
VAT on food %PrescriptionNon-prescrip-
tion (OTC)
Denmark 25,0 25,0 25,0 25,0
Norway 25,0 25,0 25,0 14,0
Germany 19,0 19,0 19,0 7,0
Italy 20,0 10,0 10,0 4,0-10,0
Finland 22,0 8,0 8,0 17,0
Greece 19,0 9,0 9,0 9,0
Belgium 21,0 6,0 6,0 6,0
Netherlands 19,0 6,0 6,0 6,0
Portugal 21,0 5,0 5,0 5,0 - 12,0
Spain 16,0 4,0 4,0 4,0-7,0
France (1) 19,6 2,1-5,5 2,1-5,5 5,5
Switzerland 7,6 2,4 2,4 2,4
Ireland (2) 21,0 0,0 - 21,0 0,0 - 21,0 0,0
Austria 20,0 20,0 20,0 10,0
Sweden 25,0 0,0 25,0 12,0
UK (3) 17,5 0,0 17,5 0,0-17,5
Facts and Figures 2008 – Medicines and Health Care
2.13 Market growth for medicines in the Nordic countries
0%
2%
4%
6%
8%
10%
12%
FinlandNorwaySwedenDenmarkAverage for theNordic Countries
Source: IMS Health Growth 2006-2007
7,2%
3,5%
6,9%
10,2%
7,1%
Sal
esgr
owth
2006-2
007
in %
Facts and Figures 2008 – Medicines and Health Care
2.14 Copayment for reimbursable medicines
0 %
10 %
20 %
30 %
40 %
50 %
60 %
70 %
80 %
90 %
100 %
Costs paid by the patient Costs paid by compulsory health insurance systemsSl
oven
ia
Den
mar
k
Finl
and
Portu
gal
Swed
en
Hun
gary
Belg
ium
Aust
ria
Gre
ece
Irela
nd
Switz
erla
nd
Ger
man
y
Nor
way
Spai
n
UK
Fran
ce
Italy
Net
herla
nds
Data from2004 Source: EFPIA
99,7
%
95,2
%
94,7
%
94,0
%
92,9
%
90,
8 %
90,
1 %
90,
0 %
90,
0 %
84,8
%
83,5
%
83,3
%
80,
1 %
74,0
%
69,4
%
65,9
%
60,
1 %
56,3
%
0,3
%
4,8
%
5,3
%
6,0
%
7,1
%
9,2
%
9,9
%
10,0
%
10,0
%
15,2
%
16,5
%
16,7
%
19,9
%
26,0
%
30,6
%
34,1
%
39,9
%
43,7
%
Facts and Figures 2008 – Medicines and Health Care
2.15 Spending on medicines as share of spending on health care in the OECD
0 % 5 % 10 % 15 % 20 % 25 %
Denmark
Norway
Switzerland
Ireland
Netherlands *
Austria
Sweden
United States
Germany
Finland
France
Canada
J apan **
Italy
Portugal
Spain 22,8 %
21,6 %
20,1 %
19,0 %
17,8 %
16,4 %
16,3 %
15,2 %
12,4 %
12,0 %
11,6 %
11,5 %
10,9 %
10,4 %
9,1 %
8,9 %
Figures from2005*Figures from2002**Figures from2004 Source: OECD
Percent
Facts and Figures 2008 – Medicines and Health Care
3.01 Sales on non-prescription medicines
0
100
200
300
400
500
600
700
800
900
1 000
20072006200520042003200220012000
Year
NO
Km
ill.P
PP
892853
833834810802
761737
Source: LMI/Farmastat Figures in PPP, 2007-currency
Facts and Figures 2008 – Medicines and Health Care
3.02 Non-prescription medicines, share of total market value (PRP) and DDD
0%
5%
10%
15%
20%
25%
DDDPRP
20072006200520042003200220012000
Source: LMI/Farmastat
Year
Per
cent
21,2%20,6%
19,8% 19,6% 19,8%19,1%
18,1%
17,2%
12,0%11,7%11,4%11,6%11,5%
12,7%13,4%
14,0%
Facts and Figures 2008 – Medicines and Health Care
3.03 The top 25 non-prescription medicines an terms of sales value
Rank 2007(2006) Medicine
Sales PPP in2007, NOK mill.
Change in salesfrom 2006
Example on area ofapplication
1 (1) Paracet 82,3 12,0 % Pain
1 (2) Otrivin 80,0 11,8 % Nasal congestion
3 (3) Ibux 64,5 16,2 % Pain
4 (4) Nicorette 54,7 9,8 % Smoking cessation
5 (5) Nicotinell 44,7 3,7 % Smoking cessation
6 (8) Pepcidduo 21,6 18,9 % Reflux
7 (6) Flux 21,0 -4,9 % Caries prevention
8 (7) Canesten 19,5 -4,1 % Fungal infections
9 (10) Livostin 15,0 10,3 % Allergy
10 (9) Zyrtec 15,0 -4,4 % Allergy
11 (13) Nycoplus C-Vitamin 11,9 5,3 % Vitamin supplement
12 (12) Rhinox 11,2 -2,7 % Nasal congestion
13 (20) Duphalac 10,7 21,4 % Constipation
14 (18) Solvipect 10,1 11,7 % Coughs
15 (11) Pinex 10,0 -15,4 % Pain
16 (14) Ibumetin 9,8 -3,8 % Nasal congestion
17 (19) Microlax 9,4 4,4 % Constipation
18 (15) Phosphoral 9,2 -4,1 % Intestine drain
19 (-) Bisolvon 9,1 34,9 % Airway diseases
20 (21) Norlevo 8,7 4,7 %Emergency contra-ception
21 (17) Minifom 8,6 -8,0 % Gastric gas
22 (25) Kaleorid 8,4 11,6 % Potassium supplement
23 (16) Zymelin 8,2 -13,6 % Nasal congestion
24 (-) Corsodyl 7,7 6,9 %Prevention of mouthinfections
25 (22) Ovesterin 7,6 -5,2 % Oestrogen deficiency
Sum top 25 559
Total sales 895 5,8 %
Share of total sales 62,4 %
Figures from 2007 Source: LMI/Farmastat
Facts and Figures 2008 – Medicines and Health Care
3.04 Non-prescription medicines sales by selected therapy groups (ATC)
NOK mill. Growth 06-07
Analgesics 206,5 8,1 %
Gastrointestinals 144,7 4,3 %
Coughs and pneumonia 134,6 7,3 %
Smoking cessation 99,5 7,0 %
Dermatologicals 88,3 9,9 %
Vitamins and minerals 42,4 -1,8 %
Allergy 31,9 -5,7 %
Hormones 16,7 -0,5 %
Sum 709,1 5,8 %
Total sales OTC 892,0 5,8 %
Figures (PPP) from 2007 Source: LMI/Farmastat
Facts and Figures 2008 – Medicines and Health Care
3.05 The top 10 pharmaceutical companies in the non-prescription medicines market
Rank 2006(2005) Company
Total sales 2006PPP, NOK mill. Sales growth Market share
1 (1) Weifa AS 166,3 9,6 % 18,6 %
2 (2) Novartis Norge AS 156,2 8,8 % 17,5 %
3 (3) Nycomed Pharma AS 107,6 -0,3 % 12,0 %
4 (-) McNeil 87,1 25,6 % 9,7 %
5 (5) Alpharma As 51,6 -8,0 % 5,8 %
6 (6) J anssen-Cilag AS 36,9 13,1 % 4,1 %
7 (-) Bayer Schering Pharma 24,0 -3,1 % 2,7 %
8 (10) Solvay Pharma AS 22,0 5,4 % 2,5 %
9 (9) GlaxoSmithKline AS 20,0 -1,6 % 2,2 %
10 (7) AstraZeneca SA 18,7 0,5 % 2,1 %
Aggregate sales top 10 compa -nies
690,4 77,1 %
Aggregate sales allnon-prescription medicines
895,0 5,8 % 100,0 %
Source: LMI/Farmastat
Facts and Figures 2008 – Medicines and Health Care
3.06 Non-prescription medicines, market share (PRP) in selected countries
Facts and Figures 2008 – Medicines and Health Care
3.07 Split by category of general sales outlets for non-prescription medicines except pharmacies
Other192; 3,2%
Gas stations1 118; 18,4%
Kiosk900; 14,8%
Health food stores372; 6,1%
Groceries3 493; 57,5%
Kilde: Norwegian Medicines Agency Number of outlets as of December 2007
Facts and Figures 2008 – Medicines and Health Care
3.08 Segmentation of sales for non-prescription medicines
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
200720062005
Nikotin(N07BA01)
Xylometazolin(R01AA07)
Paracetamol(N02BE01)
Fenazon-koffein(N02BB51)
Ibuprofen(M01AE01)
Numbers measured as DDD
Data fromthe first nine months in 2005 and 2006 for the most sold active substances
Denotes sales of medicines sold both in and outside of pharmacies
Source: Norwegian Institute of public health
33%37%38%
43%
38%
46%50%
13%17%
13%
39%
33%
14%15%14%
Active Substance
Sha
reou
tsid
eph
arm
acie
s
Facts and Figures 2008 – Medicines and Health Care
4.01 The top 10 veterinary medicines for aquaculture in terms of sales value
# Medicine Sales 2007, mill. NOK Area of application
1 Pentium forte 84,4 Fish vaccine
2 Alphaject 6-2 84,1 Fish vaccine
3 Norvax minova 6 Vet 69,2 Fish vaccine
4 Alpha max vet 36,9 Treatment against sea lice
5 Norvax compact PD Vet 30,8 Fish vaccine
6 Alphaject 5-3 Vet 13,7 Fish vaccine
7 Norvax Compact PD 6 Vet 11,9 Fish vaccine
8 Betamax Vet 10,4 Treatment against sea lice
9 Benzoak Vet 79,5 Sedation
10 Aquavac IPN Vet 60,5 Fish vaccine
Source: LMI/Farmastat
Figures measured in recommended retail prices to the customer
Facts and Figures 2008 – Medicines and Health Care
4.02 The top 10 veterinary medicines for mammels in terms of sales value
# MedicineSales 2007PPP, mill. NOK Area of application Animal segment
1 Panacur Vet 9,5 Worm treatmentBoth pets and animalsfor production
2 Nobivac DHPPI Vet 8,5 Vaccine Pets
3 Metacam Vet 8,5 Treatment of painBoth pets and animalsfor production
4 Rimadyl Vet 7,1 Treatment of pain Pets
5 Synolux Vet 6,0 Bacterial infections Pets
6 Penovet 5,3 Bacterial infectionsBoth pets and animalsfor production
7 Exspot pour on Vet 5,1 Parasite treatment Pets
8 Ivomec Vet 5,0Worm and mite treat-ment
Animals for production
9 Banmint Vet 5,0 Worm treatment Pets
10 Streptocil Forte Vet 4,6 Bacterial infections Animals for production
Source: LMI/Farmastat
Facts and Figures 2008 – Medicines and Health Care
4.03 the top 5 companies within aquaculture
# Company Sales 2006, mill. NOK
1 Pharmaq 142,8
2 Intervet Norbio 120,6
3 Scan Vacc 90,2
4 Vericore 10,8
5 Europharm 7,9
Facts and Figures 2008 – Medicines and Health Care
4.04 The top 10 companies within veterinary medicines excluding aquaculture
# Company Sales 2006, mill. NOK
1 Orion Pharma 42,7
2 Intervet 40,8
3 Schering-Plough 30,9
4 Boering Vet 26,4
5 Bayer Schering 16,2
6 Meral 15,8
7 Scanvet 13,5
8 VetXX 5
9 Novartis 4,6
10 Kela Laborator 2,2
Source: LMI/FarmastatFigures measured in recommended retail prices to the customer
Facts and Figures 2008 – Medicines and Health Care
5.01 The investment of the pharmaceutical industry in research and development
0
200
400
600
800
1 000
1 200
20062005200420032002200120001999199819971996
NO
KM
illio
n
Year
985943
864
1 047
885
818
693
812780
724706
Source: LMI Fixed 2006-currency
Facts and Figures 2008 – Medicines and Health Care
5.02 Investments in research and development, percentage of sales
0%
2%
4%
6%
8%
10%
12%
14%
2006200520042003200220012000199919981997
Per
cent
Year
Source: LMI
11,1%11,6%
11,1%
9,0%9,6% 9,5%
11,2%
8,7%
9,6%10,0%
Facts and Figures 2008 – Medicines and Health Care
5.03 Submitted clinical trials
0
50
100
150
200
250
Total number of applications to The NorwegianMedicines AgencyNumber of trials submitted by LMI’s members
200720062005200420032002Year
Sub
mitt
edcl
inic
altria
ls
Source: The Norwegian Medicines Agency
101 113 106 118 86
187 201 224 194 173 179
Facts and Figures 2008 – Medicines and Health Care
5.04 Ongoing clinical trials performed by the pharmaceutical industry
Phase of study Number of trials Number of centres Number of patients
Phase 1 6 6 16
Phase 2 37 138 3 355
Phase 3 126 706 9 123
Phase 4 40 222 1 624
Total 209 1072 14 118
Source: LMI Data from 2006
Facts and Figures 2008 – Medicines and Health Care
5.05 Industry initiated trials
0
50
100
150
200
250
300
TotalPhase 4Phase 3Phase 2Phase 1
20062005200420032002
Year
Num
berof
prot
ocol
s
Source: LMI
209
273
233
206
182
126
172159
149
124
4053
353029
3747
37
2627 61112
Facts and Figures 2008 – Medicines and Health Care
5.06 Norway`s imports and exports of medicines
0
1 000
2 000
3 000
4 000
5 000
6 000
7 000
8 000
9 000
10 000
Exports
Imports
2006
2005
2004
2003
2002
2001
2000
1999
1998
1997
1996
1995
1994
1993
1992
1991
1990
1989
Year
NO
Km
illio
n
Source: Statistics Norway/LMI
Facts and Figures 2008 – Medicines and Health Care
5.07 Number of employees in the pharmaceutical industry in Norway
0
500
1 000
1 500
2 000
2 500
3 000
3 500
4 000
4 500
5 000
20072006200520042003200220012000
4 402 4 4474 572 4 603 4 571 4 564
4 691 4 670
Em
ploy
ees
Year
Source: LMI
Facts and Figures 2008 – Medicines and Health Care
5.08 Employees in companies with production facilities in Norway
Rank 2006(2005) Medicine
Sales 2006PPP, NOKmill.
Salesgrowth
Share oftotal sales Area of application
1 (1) Enbrel 340,9 3,46 % 3,1 % Rheumatoid arthritis
2 (5) Remicade 245,8 24,99 % 2,3 % Rheumatoid arthritis
3 (4) Seretide 242,3 -4,31 % 2,2 % Asthma
4 (2) Lipitor 167,2 -29,07 % 1,5 % High cholesterol
5 (8) Humira 159,3 26,47 % 1,5% Rheumatoid arthritis
6 (6) SymbicortTurbuhaler 137,0 10,43% 1,3 % Asthma
7 (7) Zyprexa 130,1 6,93 % 1,2 % Schizophrenia
8 (11) Cipralex 115,8 17,97 % 1,1 % Depression
9 (9) Selo-Zok 101,2 -5,91 % 0,9 % High blood pressure
10 (14) Paracet 97,5 15,62 % 0,9 % Pain
11 Nexium 87,3 63,43% 0,8 % Gastric ulcer
12 (18) Atacand 82,9 83,59 % 0,8 % High blood pressure
13 (17) Cozaar 80,3 5,14 % 0,7 % High blood pressure
14 (15) Lamictal 80,3 -4,58 % 0,7 % Epilepsy
15 (22) Otrivin 79,8 11,67 % 0,7 % Nasal congestion
16 (-) Mabthera 78,1 17,81 % 0,7 % Cancer andRheumatoid arthritis
17 (19) Cozaar Comp 77,1 2,04 % 0,7 % High blood pressure
18 (16) Insulatard 76,0 -3,56 % 0,7 % Diabetes
19 (24) Herceptin 75,5 13,08 % 0,7 % Cancer
20 (20) Plavix 74,3 -0,06 % 0,7 % Thrombosis
21 (-) Ibux 73,6 16,86 % 0,7 % Pain
22 (22) Rebif 73,5 4,08 % 0,7 % Multiple sclerosis
23 (25) Singulair 71,7 7,63 % 0,7 % Asthma
24 NexiumFarmagon 70,3 -62,52 % 0,6 % Gastric ulcer
25 (-) Coaprovel 66,0 24,52 % 0,6 % High blood pressure
Aggregate sales top 25 medicines 2 883,8 26,6 %
Aggregate sales all medicines 10 866,1 2,9 % 100,0 %
Source: LMI/FarmastatParalell import is not included. The growth rate for some products willreflect variations in the splitbetween direct and paralell imports.